Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900031 | 1.00 | CHEK1 (0.46) | CHEK1FLT1ADRA1DCYP3A4CYP3A5 | |
| SCHEMBL14038877 | 0.90 | JAK2 (0.41) | CHEK1CYP3A4CYP1A2CYP2C9HPGD | |
| SCHEMBL29900121 | 0.90 | KDM4E (0.39) | CHEK1FLT1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL12921999 | 0.90 | KDM4E (0.39) | CHEK1FLT1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL12921997 | 0.90 | GRM2 (0.47) | CHEK1CYP3A4IKBKBCYP1A2CYP2C9 | |
| SCHEMBL12922002 | 0.89 | FLT1 (0.45) | CHEK1FLT1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL12922001 | 0.88 | CHEK1 (0.48) | CHEK1FLT1IKBKB | |
| SCHEMBL12922006 | 0.88 | FLT1 (0.42) | CHEK1FLT1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL12922039 | 0.86 | CYP19A1 (0.41) | FLT1NPSR1KDM4EALDH1A1 | |
| SCHEMBL8827896 | 0.82 | CHEK1 (0.47) | CHEK1IKBKBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885FLT1 2859/4885ADRA1D 164/4885 |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | CHEK2, CHEK1, PLK1 | CHEK1 2/4885FLT1 3045/4885ADRA1D 4341/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885FLT1 3045/4885ADRA1D 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.